Skip to search formSkip to main contentSkip to account menu

apolipoprotein A-I Helsinki

Known as: apoA-I (Lys(107-0)), apoA-I(Lys(107 - 0)), apoA-I Helsinki 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Apolipoprotein A-I

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
[Helsinki Declaration--next version].
Authors of the new version of The Helsinki Declaration reorganized the document, and for the first time, included the issue of… 
2012
2012
A Comparison of the Oral Health Status of Children who are Blind and Children who are Sighted in Istanbul
The World Health Organization (2011) recently estimated that 285 million people are visually impaired worldwide: 39 million are… 
2012
2012
Development of a Method to Measure preβHDL and αHDL apoA-I Enrichment for Stable Isotopic Studies of HDL Kinetics
Our understanding of HDL metabolism would be enhanced by the measurement of the kinetics of preβHDL, the nascent form of HDL… 
2010
2010
Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease.
Review
2008
Review
2008
ApoA‐I Functions and Synthesis of HDL: Insights from Mouse Models of Human HDL Metabolism
Human plasma apoA-I is a 243-residue protein that originates from a 249-aa precursor synthesized and secreted primarily by the… 
Review
2005
Review
2005
Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease
Behçet’s disease (BD) is a multisystemic vasculitis of unknown etiology characterized by oral and genital ulceration and eye… 
2001
2001
No association of the −521 C/T polymorphism in the promoter of DRD4 with novelty seeking
No association of the −521 C/T polymorphism in the promoter of DRD4 with novelty seeking SIR – Since the original reports of an… 
2001
2001
Choice of Control in Clinical Trials—Issues and Implications of ICH-E10
The International Conference on Harmonization guideline entitled “Choice of Control Group in Clinical Trials” (ICH-E10) was a… 
Highly Cited
1997
Highly Cited
1997
Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis-patients with an MHC-peptide crossreactive with autoantigen--first results.
1992
1992
Muscle cramps in chronic liver diseases and treatment with antispastic agent (eperisone hydrochloride)
To The Editor: Muscle cramps, which can be defined as involuntary and painful contractions of skeletal muscles, frequently occur… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)